Expression of mismatch repair proteins (MLH1, MSH2, MSH6 and PMS2) in endometrial cancer and their clinical significance
JIN Wei
MA Ya-qi
WANG Yun
LIU Ai-jun
Abstract：Objective To explore the expression and clinical significance of mismatch repair proteins (MLH1,MSH2,MSH6 and PMS2) in endometrial cancer (EC).Methods A total of 420 cases with EC diagnosed by the surgical pathology examination from the Department of Pathology,PLA General Hospital,and the MLH1,MSH2,MSH6 and PMS2 proteins in EC were detected by immunohistochemistry.Results In the 420 tumor tissues,the expression loss rates of MLH1,MSH2,MSH6 and PMS2 protein were 17.1％ (72/420),8.1％ (34/420),7.4％ (31/420) and 26.2％ (110/420),respectively;the total expression loss rate of four MMR protein was 34.5％ (145/420).The expression loss rate of MMR protein was 32.4％ in the endometrioid adenocarcinoma,of which the expression loss rate of MMR protein was 54.2％ in the poorly differentiated endometrioid adenocarcinoma,and the expression loss rate of every MMR protein in the different differentiated endometrioid adenocarcinoma had statistically significance (P ＜ 0.05).The expression loss rate of MMR protein was 59％ in the non-endometrioid adenocarcinoma,and the expression loss rate of MMR and PMS2 proteins had statistically significance compared to that of endometrioid adenocarcinoma (P ＜ 0.05).The expression loss rate of MSH2 protein was 18.6％ in the FIGO staging Ⅲ (P ＜0.05).The expression loss rate of MMR protein in the endometrial cancer with mucosal,superficial muscle invasion and deep muscle invasion were 35 ％ (14/40),31％ (92/299)and 48.1％ (39/81) with statistical significance (P ＜ 0.05).There were 24 patients with the expression loss rate of MMR protein in the 49 endometrial cancer patients with lymph node metastasis (P ＜ 0.05).Conclusions The expression loss rate of MMR protein is high in poorly differentiated endometrioid adenocarcinoma,FIGO staging Ⅲ,deep myometrial invasion and lymph node metastasis of endometrial cancer cases.MMR protein plays an important role in the development of endometrial cancer and indicates poor prognosis.The data of this study can effectively guide the clinical treatment and follow-up,and reduce the risk of cancer in patients and their family members.
Keywords：Endometrial cancerMismatch repair proteinImmunohistochemistry
Publication Date：2018-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 335-339 )